PriceTargets.com logo

Apogee Therapeutics - APGE Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $71.83
  • Forecasted Upside: 52.42%
  • Number of Analysts: 7
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 7 Buy Ratings
  • 0 Strong Buy Ratings
$47.13 As of 04/26/2024 01:00 AM ET
▲ +1.27 (2.77%)

This chart shows the closing price for APGE by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Apogee Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for APGE and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for APGE

Analyst Price Target is $71.83
▲ +52.42% Upside Potential
This price target is based on 7 analysts offering 12 month price targets for Apogee Therapeutics in the last 3 months. The average price target is $71.83, with a high forecast of $95.00 and a low forecast of $40.00. The average price target represents a 52.42% upside from the last price of $47.13.

This chart shows the closing price for APGE for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 7 contributing investment analysts is to buy stock in Apogee Therapeutics. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/3/2022
  • 0 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
2/1/2023
  • 0 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/2/2023
  • 0 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
7/31/2023
  • 0 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/29/2023
  • 0 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/27/2024
  • 0 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/27/2024
  • 0 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/26/2024

Latest Recommendations

  • 0 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
3/6/2024Jefferies Financial GroupBoost TargetBuy ➝ Buy$37.00 ➝ $75.00Low
3/5/2024Stifel NicolausBoost TargetBuy ➝ Buy$46.00 ➝ $95.00Low
3/5/2024GuggenheimBoost TargetBuy ➝ Buy$44.00 ➝ $91.00Low
3/5/2024WedbushReiterated RatingOutperform$40.00 ➝ $87.00Low
1/3/2024GuggenheimBoost TargetBuy ➝ Buy$29.00 ➝ $44.00Low
12/20/2023BTIG ResearchInitiated CoverageBuy$43.00Low
11/13/2023WedbushReiterated RatingOutperform$40.00Low
10/11/2023WedbushReiterated RatingOutperform$40.00Low
8/28/2023William BlairReiterated RatingOutperform$40.00Low
8/8/2023TD CowenInitiated CoverageOutperformLow
8/8/2023WedbushInitiated CoverageOutperform$40.00Low
8/8/2023GuggenheimInitiated CoverageBuy$29.00Low
8/8/2023Stifel NicolausInitiated CoverageBuy$34.00Low
8/8/2023Jefferies Financial GroupInitiated CoverageBuy$29.00Low
(Data available from 4/27/2019 forward)

News Sentiment Rating

0.70 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 2 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/30/2023
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/30/2023
  • 2 very positive mentions
  • 4 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
11/29/2023
  • 0 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/29/2023
  • 5 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/28/2024
  • 4 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/27/2024
  • 16 very positive mentions
  • 26 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/28/2024
  • 4 very positive mentions
  • 10 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/27/2024

Current Sentiment

  • 4 very positive mentions
  • 10 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

Apogee Therapeutics logo
Apogee Therapeutics, Inc., through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD. Its earlier-stage programs comprise APG990, an SQ extended half-life mAb for the treatment of AD; and APG222, an extended half-life SQ antibodies for AD. Apogee Therapeutics, Inc. was incorporated in 2022 and is headquartered in Waltham, Massachusetts.
Read More

Today's Range

Now: $47.13
Low: $44.52
High: $47.47

50 Day Range

MA: $54.24
Low: $34.50
High: $69.80

52 Week Range

Now: $47.13
Low: $14.19
High: $72.29

Volume

238,494 shs

Average Volume

461,920 shs

Market Capitalization

$2.02 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Apogee Therapeutics?

The following equities research analysts have issued reports on Apogee Therapeutics in the last twelve months: BTIG Research, Guggenheim, Jefferies Financial Group Inc., Stifel Nicolaus, TD Cowen, Wedbush, and William Blair.
View the latest analyst ratings for APGE.

What is the current price target for Apogee Therapeutics?

6 Wall Street analysts have set twelve-month price targets for Apogee Therapeutics in the last year. Their average twelve-month price target is $71.83, suggesting a possible upside of 52.4%. Stifel Nicolaus has the highest price target set, predicting APGE will reach $95.00 in the next twelve months. William Blair has the lowest price target set, forecasting a price of $40.00 for Apogee Therapeutics in the next year.
View the latest price targets for APGE.

What is the current consensus analyst rating for Apogee Therapeutics?

Apogee Therapeutics currently has 7 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe APGE will outperform the market and that investors should add to their positions of Apogee Therapeutics.
View the latest ratings for APGE.

What other companies compete with Apogee Therapeutics?

Other companies that are similar to Apogee Therapeutics include Arcellx, Immunocore, CG Oncology, Vericel and Denali Therapeutics. Learn More about companies similar to Apogee Therapeutics.

How do I contact Apogee Therapeutics' investor relations team?

Apogee Therapeutics' physical mailing address is 221 Crescent Street, Building 17 Suite 102b, Waltham, MA 02453, United States. The company's listed phone number is 650-394-5230 and its investor relations email address is [email protected]. The official website for Apogee Therapeutics is www.apogeetherapeutics.com. Learn More about contacing Apogee Therapeutics investor relations.